

Esther E Freeman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1317792/publications.pdf>

Version: 2024-02-01

73
papers

2,977
citations

361413

20
h-index

175258

52
g-index

76
all docs

76
docs citations

76
times ranked

3607
citing authors

#	ARTICLE	IF	CITATIONS
1	Proposing a standardized assessment of COVID-19 vaccine-associated cutaneous reactions. <i>Journal of the American Academy of Dermatology</i> , 2023, 88, 237-241.	1.2	7
2	Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 283-286.	5.7	12
3	Varicella-zoster and herpes simplex virus reactivation post-COVID-19 vaccination: a review of 40 cases in an International Dermatology Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	2.4	53
4	Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 113-121.	1.2	113
5	Skin reactions to COVID-19 vaccines: An American Academy of Dermatology/International League of Dermatological Societies registry update on reaction location and COVID vaccine type. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, e165-e167.	1.2	21
6	Introducing the Global Health and Equity section in the <i>British Journal of Dermatology</i> . <i>British Journal of Dermatology</i> , 2022, 186, 201-202.	1.5	3
7	Chilblains and COVID-19: An Update on the Complexities of Interpreting Antibody Test Results, the Role of Interferon γ , and COVID-19 Vaccines. <i>JAMA Dermatology</i> , 2022, 158, 217.	4.1	4
8	Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 226, 1231-1236.	4.0	1
9	Delayed large local reactions to Moderna COVID-19 vaccine: A follow-up report after booster vaccination. <i>JAAD International</i> , 2022, 8, 3-6.	2.2	6
10	Urticaria 12 Days After COVID-19 mRNA Booster Vaccination. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1702.	7.4	11
11	Nodules in a sporotrichoid (lymphangitic) distribution. <i>BMJ, The</i> , 2022, 376, e067649.	6.0	0
12	Cutaneous reactions following booster dose administration of COVID-19 mRNA vaccine: A first look from the American Academy of Dermatology/International League of Dermatologic Societies registry. <i>JAAD International</i> , 2022, 8, 49-51.	2.2	13
13	Understanding Diagnostic Delays for Kaposi Sarcoma in Kenya: A Qualitative Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 494-503.	2.1	3
14	A type III effectiveness-implementation hybrid evaluation of a multicomponent patient navigation strategy for advanced-stage Kaposi's sarcoma: protocol. <i>Implementation Science Communications</i> , 2022, 3, 50.	2.2	2
15	Chronic spontaneous urticaria after COVID-19 primary vaccine series and boosters. <i>JAAD Case Reports</i> , 2022, 25, 63-66.	0.8	13
16	Healthcare Costs and Financial Barriers to Diagnosis and Treatment of People Living with HIV-Associated Kaposi's Sarcoma in Western Kenya: A Qualitative Analysis. <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
17	Stigma in the Diagnosis and Treatment of HIV-associated Kaposi's Sarcoma. <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
18	Vitiligo of the arm after COVID-19 vaccination. <i>JAAD Case Reports</i> , 2022, 28, 142-144.	0.8	9

#	ARTICLE	IF	CITATIONS
19	Telling the story of intersectional stigma in HIV-associated Kaposi's sarcoma in western Kenya: a convergent mixed-methods approach. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	3
20	Barriers and facilitators to chemotherapy initiation and adherence for patients with HIV-associated Kaposi's sarcoma in Kenya: a qualitative study. <i>Infectious Agents and Cancer</i> , 2022, 17, .	2.6	1
21	Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis. <i>The Lancet Global Health</i> , 2022, 10, e1179-e1188.	6.3	5
22	Feasibility and implementation of portable confocal microscopy for point-of-care diagnosis of cutaneous lesions in a low-resource setting. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 499-502.	1.2	6
23	Timing of PCR and antibody testing in patients with COVID-19-associated dermatologic manifestations. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 505-507.	1.2	20
24	Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 60-71.	2.9	136
25	Developing a Platform for Global Health Dermatology Mentorship and Collaboration. <i>Dermatologic Clinics</i> , 2021, 39, 73-82.	1.7	4
26	Novel Diagnostics for Kaposi Sarcoma and Other Skin Diseases in Resource-Limited Settings. <i>Dermatologic Clinics</i> , 2021, 39, 83-90.	1.7	4
27	Emerging Evidence of the Direct Association Between COVID-19 and Chilblains. <i>JAMA Dermatology</i> , 2021, 157, 238.	4.1	9
28	Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 313-314.	9.1	90
29	Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. <i>New England Journal of Medicine</i> , 2021, 384, 1273-1277.	27.0	226
30	Skin Biopsy Equipment Availability Across 7 Low-Income Countries. <i>JAMA Dermatology</i> , 2021, 157, 462.	4.1	2
31	Cold and COVID: recurrent pernio during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2021, 185, 214-216.	1.5	11
32	Identifying gaps in global health dermatology: a survey of GLODERM members. <i>British Journal of Dermatology</i> , 2021, 185, 212-214.	1.5	3
33	Pernio after COVID-19 vaccination. <i>British Journal of Dermatology</i> , 2021, 185, 445-447.	1.5	26
34	Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. <i>Clinics in Dermatology</i> , 2021, 39, 467-478.	1.6	9
35	Response to: "Comment on "The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries". <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e293-e294.	1.2	1
36	Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 46-55.	1.2	643

#	ARTICLE	IF	CITATIONS
37	Low-cost, chromatic confocal endomicroscope for cellular imaging in vivo. <i>Biomedical Optics Express</i> , 2021, 12, 5629.	2.9	9
38	Beyond T Staging in the "Treat-All" Era: Severity and Heterogeneity of Kaposi Sarcoma in East Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 87, 1119-1127.	2.1	10
39	Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 750-751.	2.9	73
40	Feasibility of Rapid Case Ascertainment for Cancer in East Africa: An Investigation of Community-Representative Kaposi Sarcoma in the Era of Antiretroviral Therapy. <i>Cancer Epidemiology</i> , 2021, 74, 101997.	1.9	4
41	Guidelines of care for the management of actinic keratosis. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, e209-e233.	1.2	56
42	Guidelines of care for the management of actinic keratosis: Executive summary. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 945-955.	1.2	10
43	Global Disparities in Skin Cancer Services at HIV Treatment Centers across 29 Countries. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2533-2536.e2.	0.7	4
44	How Coronavirus Disease 2019 Changed Dermatology Practice in 1 Year Around the World. <i>Dermatologic Clinics</i> , 2021, 39, 639-651.	1.7	3
45	COVID-19 Vaccines and the Skin. <i>Dermatologic Clinics</i> , 2021, 39, 653-673.	1.7	97
46	COVID-19 and Dermatology: One Year in Review. <i>Dermatologic Clinics</i> , 2021, 39, xv-xvi.	1.7	0
47	Dermatology COVID-19 Registries. <i>Dermatologic Clinics</i> , 2021, 39, 575-585.	1.7	12
48	Dermatology on the global stage: The role of dermatologists in international health advocacy and COVID-19 research. <i>International Journal of Women's Dermatology</i> , 2021, 7, 653-659.	2.0	3
49	Skin-colored bandages: A call to action. <i>Pediatric Dermatology</i> , 2021, 38, 185-186.	0.9	0
50	A strategy for empowering clinicians and increasing innovation: the Magic Wand Initiative. <i>Archives of Dermatological Research</i> , 2020, 313, 599-602.	1.9	2
51	The role of dermatology in Kaposi sarcoma diagnosis across three regions in sub-Saharan Africa. <i>Journal of the American Academy of Dermatology</i> , 2020, 85, 1414-1417.	1.2	2
52	Miniature, hyperchromatic objective lens for chromatic confocal endomicroscope. , 2020, , .		0
53	A positively selected FBN1 missense variant reduces height in Peruvian individuals. <i>Nature</i> , 2020, 582, 234-239.	27.8	39
54	Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 486-492.	1.2	161

#	ARTICLE	IF	CITATIONS
55	International collaboration and rapid harmonization across dermatologic COVID-19 registries. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e261-e266.	1.2	13
56	Time to address disparities in the standard of care for Kaposi sarcoma. <i>Lancet, The</i> , 2020, 395, 1169-1170.	13.7	4
57	The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1118-1129.	1.2	288
58	Global resource shortages during COVID-19: Bad news for low-income countries. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008412.	3.0	165
59	Modernizing clinical practice guidelines for the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1487-1489.	1.2	9
60	Real-world use of chemotherapy for Kaposi's sarcoma in a large community-based HIV primary care system in Kenya. <i>BMC Cancer</i> , 2020, 20, 71.	2.6	9
61	Creating dermatology guidelines for COVID-19: The pitfalls of applying evidence-based medicine to an emerging infectious disease. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, e231-e232.	1.2	14
62	25 Years of Kaposi Sarcoma Herpesvirus: Discoveries, Disparities, and Diagnostics. <i>JCO Global Oncology</i> , 2020, 6, 505-507.	1.8	3
63	The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 509-510.	1.2	56
64	Task Shifting in Dermatology—A Call to Action—Reply. <i>JAMA Dermatology</i> , 2018, 154, 628.	4.1	0
65	Smartphone confocal microscopy for imaging cellular structures in human skin in vivo. <i>Biomedical Optics Express</i> , 2018, 9, 1906.	2.9	50
66	Task Shifting in Dermatology. <i>JAMA Dermatology</i> , 2017, 153, 1179.	4.1	11
67	Global Burden of Skin Disease: Inequities and Innovations. <i>Current Dermatology Reports</i> , 2017, 6, 204-210.	2.1	190
68	Updating vital status by tracking in the community among patients with epidemic Kaposi sarcoma who are lost to follow-up in sub-Saharan Africa. <i>BMC Cancer</i> , 2017, 17, 611.	2.6	10
69	Treatment of Dermatological Conditions Associated with HIV/AIDS: The Scarcity of Guidance on a Global Scale. <i>AIDS Research and Treatment</i> , 2016, 2016, 1-21.	0.7	5
70	Pitfalls of practicing cancer epidemiology in resource-limited settings: the case of survival and loss to follow-up after a diagnosis of Kaposi's sarcoma in five countries across sub-Saharan Africa. <i>BMC Cancer</i> , 2016, 16, 65.	2.6	25
71	A Seat at the Big Table: Expanding the Role of Dermatology at the World Health Organization and Beyond. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2663-2665.	0.7	12
72	Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. <i>The Cochrane Library</i> , 2014, , CD003256.	2.8	60

#	ARTICLE	IF	CITATIONS
73	Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics. <i>Sexually Transmitted Infections</i> , 2007, 83, i17-i24.	1.9	96